Key result
Clinical and post-marketing data indicate that the cardiac toxicity observed in preclinical mouse models does not translate to humans treated with onasemnogene abeparvovec, with reported cardiac events primarily secondary to the underlying spinal muscular atrophy.
Why the study?
The heart is a known target organ of rAAV toxicity in animals, requiring cardiac monitoring after onasemnogene abeparvovec dosing in humans, but translational cardiac safety data needed comprehensive description.
Cardiac toxicity observed in mice following onasemnogene abeparvovec administration does not translate to humans, where cardiac events are primarily secondary to the underlying spinal muscular atrophy rather than direct drug toxicity.
Answers are grounded in this paper and cite their sources.
Supports reassuring cardiac safety for onasemnogene abeparvovec in SMA; leaves open need for prospective validation.
Human gene replacement therapies such as onasemnogene abeparvovec (OA) use recombinant adeno-associated virus (rAAV) vectors to treat monogenic disorders. The heart and liver are known target organs of toxicity in animals; with cardiac and hepatic monitoring recommended in humans after OA dosing. This manuscript provides a comprehensive description of cardiac data from preclinical studies and clinical sources including clinical trials, managed access programs and the post-marketing setting following intravenous OA administration through 23 May 2022. Single dose mouse GLP-Toxicology studies revealed dose-dependent cardiac findings including thrombi, myocardial inflammation and degeneration/regeneration, which were associated with early mortality (4-7 weeks) in the high dose groups. No such findings were documented in non-human primates (NHP) after 6 weeks or 6 months post-dose. No electrocardiogram or echocardiogram abnormalities were noted in NHP or humans. After OA dosing, some patients developed isolated elevations in troponin without associated signs/symptoms; the reported cardiac adverse events in patients were considered of secondary etiology (e.g. respiratory dysfunction or sepsis leading to cardiac events). Clinical data indicate cardiac toxicity observed in mice does not translate to humans. Cardiac abnormalities have been associated with SMA. Healthcare professionals should use medical judgment when evaluating the etiology and assessment of cardiac events post OA dosing so as to consider all possibilities and manage the patient accordingly.
No takes yet. Share an insight, caveat, or question.
Chand et al. (2023) conducted a review in Spinal muscular atrophy (SMA) (n=2,370). Onasemnogene abeparvovec was evaluated on Cardiac adverse events. Clinical and post-marketing data indicate that the cardiac toxicity observed in preclinical mouse models does not translate to humans treated with onasemnogene abeparvovec, with reported cardiac events primarily secondary to the underlying spinal muscular atrophy.
Synapse has enriched 10 related papers. Consider them for comparative context: